Michael Wang: Our Phase I TRANSCEND trial demonstrated that Liso-cel results in consistently high objective response rates

Michael Wang, Professor in the Department of Lymphoma/Myeloma and the Department of Stem Cell Transplantation and Cellular Therapy at MD Anderson Cancer Center shared on X:

“Our Phase I TRANSCEND trial demonstrated that Liso-cel results in consistently high objective response rates and complete response rates in patients with heavily pretreated Relapsed/Refractory Mantle Cell Lymphoma, including those with high-risk disease characteristics.”

Read further.
Source: Michael Wang/X

About OncoDaily

OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.

OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.

The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”